

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長 江 生 命 科 技 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “Board”) of CK Life Sciences Int'l. (Holdings) Inc. (the “Company” and together with its subsidiaries, the “Group”) wishes to inform shareholders of the Company (the “Shareholders”) and potential investors that based on the preliminary review of the Group's unaudited consolidated management accounts for the six months ended 30 June 2024 (the “Reporting Period” and the “Management Accounts”, respectively) and the information that is currently available to the Board, the Group expects to report a material reduction in the profit attributable to the Shareholders for the Reporting Period compared to that for the six months ended 30 June 2023. The magnitude of this reduction is expected to be larger than that reported in the Company's 2023 Annual Report and is attributable to the continued high finance costs which impacted the overall profit of the Group for the Reporting Period. During the Reporting Period, the Group's nutraceutical business remained stable, while the agriculture-related business was under pressure. Further details will be disclosed in the interim results announcement of the Company to be published on 13 August 2024.

The Company is still in the process of finalising the financial results of the Group for the Reporting Period. The information contained in this announcement is only based on the preliminary review and analysis of the Management Accounts and the information currently available to the Board and is not based on any figures or information audited or reviewed by the Company's independent auditor or reviewed by the audit committee of the Board and may be subject to change. The Shareholders and potential investors are advised to read carefully the interim results announcement of the Company to be published on 13 August 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board
CK Life Sciences Int'l. (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 6 August 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).